NovaBay Pharmaceuticals Announces Closing of $3.87 Million Underwritten Public Offering, Including Partial Exercise of Overallotment Option Jul 29, 2024 04:05PM
NovaBay Pharma (NBY) Announces Pricing of $3.5 Million Underwritten Public Offering Jul 26, 2024 08:31AM
NovaBay Pharmaceuticals Announces Pricing of $3.5 Million Underwritten Public Offering Jul 26, 2024 08:30AM
NovaBay Pharma (NBY) Reports Prelim Q2 Revenue of $2.4M Jul 11, 2024 06:51AM
NovaBay Pharmaceuticals Reports Preliminary Second Quarter 2024 Net Revenue of $2.4 Million Jul 11, 2024 06:50AM


Apr 27, 2023 04:47PM NovaBay Pharma (NBY) Announces $3M Convertible Note Financing
Apr 27, 2023 04:47PM NovaBay Pharmaceuticals Announces $3.0 Million Convertible Note Financing
Sep 23, 2022 06:50AM NovaBay Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference
Sep 9, 2022 08:01AM NovaBay Pharma (NBY) Enters Into Agreements For a Private Placement and Warrant Reprice Transactions To Raise Up to $5.3 Million
Sep 9, 2022 08:00AM NovaBay Pharmaceuticals Enters Into Agreements For a Private Placement and Warrant Reprice Transactions To Raise Up to $5.3 Million
Nov 1, 2021 08:35AM NovaBay Pharma (NBY) Prices 15,000 Share Preferred Private Placement at $1,000/sh
Nov 1, 2021 08:30AM NovaBay Pharmaceuticals Announces Pricing of $15.0 Million Private Placement
Jul 8, 2021 06:50AM NovaBay Pharmaceuticals to Participate in Two July Investment Conferences
Sep 18, 2019 06:41AM Ladenburg Thalmann Starts NovaBay Pharmaceuticals (NBY) at Buy
Sep 3, 2019 06:50AM NovaBay Pharmaceuticals to Present at Two Investment Conferences in September
Aug 9, 2019 09:24AM NovaBay Pharma (NBY) Prices 4.2M Shares Registered Direct Offering at $1/Sh
Aug 9, 2019 09:22AM NovaBay Pharmaceuticals Announces Pricing of $4.2 Million Registered Direct Offering